FDA Approves PROGESTERONE VAGINAL INSERTS — Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals USA announced today the approval of its generic progesterone vaginal inserts (ANDA 216363) by the FDA, a critical move to capture market share in the short-term progestogen therapy space. This launch highlights Glenmark’s ongoing expansion in the female health sector and intensifies pricing pressure on the established branded equivalents currently dominating the market.